Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3968621 Alone or With Ezabenlimab in Advanced Solid Tumours
NCT07851103Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Primary completion
- Sep 2030
- Countries
- 5
01
Overview
Phase 1, open-label trial of BI 3968621 in solid tumor and kidney cancer (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-Limiting Toxicities at 21 days and Objective Response up to 2 years. Started Oct 2026; status: recruiting.
02
Drugs
BI 3968621
03
Conditions
solid tumorkidney cancer
Beyond the preview
Go deeper on NCT07851103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07851103.